Effects of intravenous administration of recombinant Phα1β toxin in a mouse model of fibromyalgia

Abstract

This study investigated the effects of intravenous (iv) administration of recombinant Phα1β toxin, pregabalin, and diclofenac by the intrathecal route using an animal model fibromyalgia (FM). The reserpine administration (0.25 mg/kg s. c) once daily for three consecutive days significantly induced hyperalgesia, immobility time, and sucrose consumption in mice on the 4th day. Reserpine caused hyperalgesia on the mechanical and thermal hyperalgesia on the 4th day was reverted by recombinant Phα1β (0.2 mg/kg iv) and pregabalin (1.25 μmol/site i. t) treatments. In contrast, diclofenac (215 nmol/site i. t) was ineffective. Recombinant Phα1β toxin, pregabalin, and diclofenac did not affect the depressive-like behavioural effect induced by reserpine on mice during the forced swim and sucrose consumption tests. The data confirmed the analgesic effect of the recombinant Phα1β toxin administered intravenously in a fibromyalgia mouse model.

Keywords: Calcium channel blocker; Diclofenac; Pregabalin; Recombinant toxin; TRPA1 antagonist fibromyalgia.